On January 6, 2021 NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, reported that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual J.P. Morgan Healthcare Conference (Press release, NantKwest, JAN 6, 2021, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-executive-chairman-dr-patrick-soon-shiong-present-39th [SID1234573570]). He will make a formal presentation and answer questions at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday, January 13, 2021. Dr. Soon-Shiong will discuss NantKwest’s previously announced agreement to combine in a stock-for-stock transaction with ImmunityBio, Inc. The combination, which is expected to close in the first half of 2021, will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. Dr. Soon-Shiong will also provide an update on the clinical progress of the two companies’ individual and collaborative therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and associated presentation materials will be available on the NantKwest website at https://ir.nantkwest.com/ and on the ImmunityBio website at View Source A replay will be available after the completion of the presentation.